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Abstract The NFUB family of transcription factors is regulated
by inhibitory IUB proteins. A diversity of stimuli leads to the
phosphorylation and subsequent degradation of IUB, releasing
NFUB to act on its target genes. Calmodulin (CaM) is a key
regulator of numerous cellular processes and is the predominant
intracellular receptor for Ca2+ signals. Here we report that
several CaM antagonists inhibit the activation of NFUB, and that
this is due to the prevention of inducible IUB phosphorylation.
Our results suggest that CaM is involved in the phosphorylation
of IUB, a finding that may help in elucidating the mechanism of
this critical step of NFUB activation.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
NFUB is a large family of structurally and functionally
related transcription factors [1]. They control a wide variety
of genes, particularly genes involved in regulation of the im-
mune system, development and growth control, and are also
utilised by viruses such as HIV to initiate and maintain in-
fection [1,2]. The regulation of NFUB is a paradigm for the
control of transcription through subcellular location. In most
cells, NFUB is sequestered in the cytoplasm through associa-
tion with inhibitory IUB proteins. Upon cellular stimulation,
IUB becomes rapidly phosphorylated, marking it for degrada-
tion by the ubiquitin-proteasome pathway [3]. NFUB is con-
sequently released, exposes its nuclear localisation sequence
and translocates to the nucleus to act on its target genes.
NFUB can be activated by numerous stimuli, most of which
are stress or pathogenic signals [1]. These include in£amma-
tory cytokines, mitogens, viruses, bacterial lipopolysaccharide,
UV and gamma radiation and oxidative stress. Although
these agents activate distinct signal transduction pathways,
they converge at the level of IUB phosphorylation. Therefore
much attention has been focused on this critical phosphoryl-
ation of IUB. Recent studies have identi¢ed several kinases
that are involved in IUB phosphorylation. The double-
stranded RNA-dependent protein kinase PKR [4,5], the mito-
gen activated 90-kDa ribosomal S6 kinase (p90rsk) [6,7] and
two recently identi¢ed kinases, IKKK and IKKL [8^12], me-
diate IUB phosphorylation in response to speci¢c stimuli.
IKKK and IKKL are part of large (500^900-kDa) multisub-
unit complexes (reviewed in [13]), implicating that IUB phos-
phorylation is a complex process involving several compo-
nents. Although the players involved are gradually being
revealed, the mechanism of IUB phosphorylation is not yet
fully understood.
The widely used secondary messenger Ca2 is involved in
NFUB regulation. This was ¢rst evidenced by the analysis of
NFUB activation in response to T-cell stimulation. T-cell re-
ceptor (TCR) stimulation initiates a bipartite signal transduc-
tion cascade involving both activation of a kinase cascade and
an increase in intracellular Ca2. This stimulation can be
pharmacologically mimicked by co-treating cells with a phor-
bol ester mitogen, which directly activates protein kinase C
and initiates the kinase cascade, and a Ca2 ionophore [14].
NFUB is activated by phorbol ester alone, but activation is
enhanced by co-treatment with a Ca2 ionophore [15]. This
Ca2 co-induction is mediated by the Ca2/calmodulin (CaM)
dependent protein phosphatase calcineurin (CaN), since the
CaN inhibitors cyclosporin A and FK506 prevent the Ca2-
mediated activation of NFUB [15,16], and introduction of a
constitutively active CaN mimics the Ca2 e¡ect [16^18].
There is increasing evidence that Ca2 is required by several
other inducers of NFUB. Ca2 chelators inhibit NFUB activa-
tion in response to okadaic acid [19], sphingosine-1-phosphate
[20] and protein overloading of the endoplasmic reticulum
[21,22]. Furthermore, Ca2 chelators block the constitutive
degradation of IUB in a B-cell line [23]. The Ca2 signal in-
duced by sphingosine-1-phosphate is mediated by CaN [20],
but it is not known if CaN mediates NFUB activation by all
Ca2-dependent inducers.
CaN appears to accelerate IUB phosphorylation and degra-
dation [16], but the mechanism by which it does so is not
known. We began our study by addressing the role of CaM
in the regulation of CaN during NFUB activation. CaM is a
ubiquitously expressed, highly conserved protein that is essen-
tial for numerous cellular processes and is the key mediator of
Ca2 signals [24,25]. Upon binding Ca2 it undergoes a con-
formational change that allows it to interact with its many
target proteins, including CaN. Surprisingly, we found that
inhibitors of CaM prevent both CaN-dependent and CaN-
independent NFUB activation. Our results suggest that CaM
has an essential role in the phosphorylation of IUB, a ¢nding
that may provide an insight into the mechanism of what is
emerging as a complex regulation of IUB phosphorylation.
2. Materials and methods
2.1. Plasmids
The luciferase reporter plasmids used in this study were derived
from the E47 luciferase reporter [26] by replacing the WE5+WE2 se-
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quences with the following sequences: two copies of the NFUB site
from the immunoglobulin U light chain enhancer [27] to create the
NFUB reporter plasmid pGL2-(IgUB)2, or a segment from the murine
TCRL gene enhancer (nucleotides 619^737) [28] to create the TCRL
enhancer reporter plasmid pGL2-TCRL. The CMV-Lgal normalisa-
tion plasmid has been described previously [29]. The calmodulin ex-
pression construct pcDNA1/AMP-mCaM was created by cloning the
murine CaM A cDNA from pcDNA1-mCaM [30] into pcDNA1/
AMP (Invitrogen).
2.2. Cell culture and transient transfections
Jurkat T-cells and K562 pre-erythromyelocytic cells were main-
tained in RPMI supplemented with 5% FCS and antibiotics. Jurkat
T-cells were transiently transfected by electroporation with 3 Wg re-
porter plasmid and 2 Wg CMV-Lgal with or without 10 Wg expression
plasmid as described [26]. Unless otherwise indicated, drugs were
added 8 h after electroporation and cells were harvested 2 h later.
Luciferase activities were measured with Luciferase assay system
(Promega). All transfection results are from 3 or more independent
transfections þ S.E.M.
2.3. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described [31]. One Wg of extract
was incubated with DNA probe in 10 mM Tris (pH 7.5), 1 mM DTT,
1 mM EDTA, 5% glycerol, 120 mM NaCl and 2 Wg poly(dI-dC) for
15 min at room temperature and electrophoresed through Tris-borate-
EDTA 6% acrylamide gels. EMSAs were performed with a 32P-la-
beled immunoglobulin U light chain enhancer UB sequence, 5P-GTCA-
GAGGGGACTTTCCGAGAGGTA-3P. The NFUB complexes could
be speci¢cally competed with the UB DNA sequence.
2.4. Western blot analysis
Cytoplasmic extracts were prepared as described [31] except includ-
ing the phosphatase inhibitors NaF (50 mM), Na3VO4 (1 mM), L-
glycerophosphate (20 mM) and sodium pyrophosphate (10 mM).
Fifty-Wg extracts were separated by SDS-PAGE followed by Western
blot analysis using anti-IUBK C-15 antibody (Santa Cruz) and the
ECL kit (Amersham).
3. Results
3.1. Activation of NFUB is dependent on calmodulin
To further analyse CaN activation of NFUB, we asked
whether CaN is dependent on CaM during NFUB activation.
The T-cell line Jurkat was transiently transfected with an
NFUB-driven luciferase reporter and measured for NFUB ac-
tivity in response to stimulation in the presence of CaN or
CaM inhibiting drugs. TCR stimulation was mimicked by co-
treating cells with the phorbol ester mitogen phorbol 12-myr-
istate 13-acetate (PMA) and the Ca2 ionophore ionomycin.
As previously reported [15,32], the immunosuppressive CaN
inhibitor cyclosporin A completely inhibited the Ca2 co-in-
duction of NFUB, but had no e¡ect on PMA induction (Fig.
1). Surprisingly, the classical CaM inhibitor N-(6-aminohex-
yl)-5-chloro-1-naphthalenesulfonamide (W7) [33] not only in-
hibited the Ca2 co-induction but also completely inhibited
PMA induction of NFUB (Fig. 1). This suggests that CaM
is essential for NFUB activation and that its role is not limited
to the activation of CaN.
To further investigate this CaM dependence of NFUB acti-
vation, we analysed the e¡ects of several di¡erent CaM inhib-
iting drugs. Fig. 2A shows that W7 inhibits PMA induction of
NFUB in a dose dependent manner, with an IC50 of 7 WM. N-
(6-Aminohexyl)-1-naphthalenesulfonamide (W5), an analogue
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Fig. 1. Calmodulin is necessary for NFUB activation. Jurkat cells
were transiently transfected with the NFUB-driven luciferase report-
er and the CMV-Lgal normalisation plasmid, and the e¡ects of vari-
ous drugs on NFUB activity were analysed. PMA (25 ng/ml), iono-
mycin (1 Wg/ml), the CaN inhibitor cyclosporin A (CsA, 100 nM)
and the CaM inhibitor W7 (25 WM) were added where indicated.
Values are shown as normalised -fold activation compared to un-
treated cells.
Fig. 2. A variety of CaM inhibitors prevent NFUB activation. A
and B: Jurkat cells transfected as in Fig. 1 were treated with vari-
ous concentrations of the indicated CaM inhibiting drugs. Tran-
scription from the CMV promoter of the CMV-Lgal control plasmid
(dashed line) and inhibition of PMA (25 ng/ml) induced NFUB ac-
tivity (solid line) is shown. L-Galactosidase activity and PMA induc-
tion in the absence of inhibitor was set to 100%. C: Jurkat cells
transfected as in Fig. 1, with the addition of the indicated expres-
sion plasmid, were stimulated with PMA (25 ng/ml) with increasing
concentrations of W7. PMA induction in the absence of inhibitor
was set to 100%.
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of W7 that is a less potent CaM inhibitor [33,34], was corre-
spondingly less inhibiting, with an IC50 of 26 WM (Fig. 2A).
This inhibitory e¡ect was also seen with three other CaM
inhibitors, N-(4-aminobutyl)-5-chloro-2-naphthalenesulfon-
amide (W13), N-(4-aminobutyl)-2-naphthalenesulfonamide
(W12) (a less potent analogue of W13 [33,35]) and calmida-
zolium [36,37], with IC50 values of 10, 36 and 3 WM, respec-
tively (Fig. 2B). CaM inhibitors did not a¡ect transcription
from the CMV promoter of the CMV-Lgal control plasmid
(Fig. 2A and B), showing that the inhibition of NFUB activity
is speci¢c.
Although these ¢ve di¡erent CaM inhibitors prevent the
activation of NFUB and the relative inhibition correlates
with their relative CaM inhibiting properties, it is not ex-
cluded that the e¡ect of these drugs is due to interaction
with another cellular protein rather than CaM. If their e¡ect
is through speci¢c inhibition of CaM, then overexpression of
CaM should decrease their potency. This is a technically dif-
¢cult approach since CaM is a highly abundant protein. Fur-
thermore, it has been shown that changes in CaM mRNA are
not accompanied by corresponding changes in protein levels,
illustrating that CaM is mainly regulated at the post-tran-
scriptional level [38^40]. Nonetheless, compared to cells tran-
siently transfected with an empty expression plasmid, cells
transfected with a CaM expression plasmid required approx-
imately 1.4-fold more W7 to achieve the equivalent inhibition
of NFUB (Fig. 2C). This strongly argues that the inhibition of
NFUB by these drugs is due to speci¢c inhibition of CaM.
3.2. Calmodulin acts at an early step of NFUB activation
We have shown that somewhere in the phorbol ester in-
duced signal transduction pathway, CaM is required for the
activation of NFUB. If the CaM dependent step is a very early
event, then other phorbol ester activated pathways should
also be dependent on CaM. To address this issue, we analysed
the e¡ect of W7 on another characterised phorbol ester acti-
vated pathway. Transcription from the TCRL gene enhancer
is highly phorbol ester inducible [41], and the region respon-
sible for the phorbol ester induction has been mapped to
elements that bind Ets and CBF/PEBP2/AML transcription
factors [42]. We transfected Jurkat cells with a luciferase re-
porter driven by this phorbol ester responsive segment, and
the e¡ect of W7 on PMA induction was examined. Fig. 3A
shows that PMA induced transcription from the TCRL re-
porter was not signi¢cantly inhibited by concentrations of
W7 that dramatically inhibited PMA induction of NFUB.
This shows that the CaM antagonist does not inhibit PMA
signalling in general and that CaM acts at a stage where these
PMA induced signalling events have diverged.
To further map the CaM-dependent step of NFUB activa-
tion, Jurkat cells transfected with the NFUB-driven luciferase
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Fig. 3. Calmodulin acts at an early step of NFUB activation. A: Jurkat cells transfected with the indicated luciferase reporter were stimulated
for 4 h with PMA (25 ng/ml) in the presence of increasing concentrations of W7. PMA induction in the absence of inhibitor was set to 100%.
B: Jurkat cells transfected as in Fig. 1 were stimulated with PMA (25 ng/ml) in the absence or presence of W7 (25 WM) added at the indicated
times. NFUB activity in the presence of PMA and absence of W7 was set to 100%. C: EMSA of nuclear extracts prepared from Jurkat cells
treated with PMA (25 ng/ml) in the absence or presence of W7 (25 WM) for the indicated times. D: EMSA of nuclear extracts prepared from
K562 cells treated with PMA (50 ng/ml) in the absence or presence of W7 (65 WM) for the indicated times.
Fig. 4. Calmodulin is necessary for the induced phosphorylation of
IUB. Western blot analysis of IUBK from Jurkat cells stimulated
with PMA (25 ng/ml) or PMA and ionomycin (1 Wg/ml) in the ab-
sence or presence of W7 (25 WM) for the indicated times is shown.
The slower migrating band (P-IUB) is the induced phosphorylated
form of IUBK [43].
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reporter were treated with W7 at various times after PMA
stimulation. Addition of W7 just 10, 20 or 30 min after
PMA stimulation had a decreasing e¡ect on NFUB activation,
with almost no e¡ect if W7 was added after 30 min (Fig. 3B).
Since more than 95% of the luciferase was made later than 30
min after PMA stimulation (data not shown), this indicates
that CaM is not involved late in transcription or translation
but rather in an early step of NFUB activation.
To determine if CaM is involved before or after nuclear
translocation of NFUB, nuclear extracts were prepared from
cells stimulated with PMA in the absence or presence of W7
and assayed for NFUB DNA binding activity. Fig. 3C shows
that the PMA induced nuclear accumulation of NFUB was
abolished in the presence of W7. PMA induced nuclear accu-
mulation of NFUB in the pre-erythromyelocytic cell line K562
was also inhibited by W7 (Fig. 3D), demonstrating that CaM
is necessary for NFUB activation in unrelated cell lines. Col-
lectively, these data suggest that CaM acts at a pre-nuclear
step, and is a requirement of NFUB activation in both T- and
non-T-cells.
3.3. Induced phosphorylation of IUB requires calmodulin
NFUB activating signals lead to the chronological phos-
phorylation, ubiquitination and degradation of IUB, followed
by nuclear translocation of the released NFUB. The pre-nu-
clear CaM-dependent step could therefore be at the level of
release of NFUB from IUB or a subsequent translocation step.
Fig. 4 shows Western blot analysis of IUBK from Jurkat cells
stimulated in the absence or presence of W7. Stimulation with
PMA or PMA plus ionomycin results in the phosphorylation
of IUBK, as seen by a change in its electrophoretic mobility,
followed by its rapid degradation [43] (Fig. 4). In the presence
of W7, however, there was no appearance of phosphorylated
IUBK and it was not degraded (Fig. 4). Thus, we conclude that
CaM is necessary for the induced phosphorylation of IUB and
consequently for its subsequent degradation and release of
NFUB.
4. Discussion
The regulation of NFUB has received much attention over
the years, both because NFUB is a key component of numer-
ous important transcriptional responses and because its regu-
lation has proved intriguing. When a cell is appropriately
stimulated, the NFUB inhibitor IUB rapidly becomes phos-
phorylated, labelling it for degradation by the ubiquitin-pro-
teasome pathway and thus releasing NFUB to translocate to
the nucleus and act on its target genes [3]. Here we present
evidence that the Ca2-binding protein CaM is essential for
the activation of NFUB. We show that a variety of CaM
inhibitors prevent NFUB activation in response to phorbol
ester, and that NFUB activation is blocked by CaM inhibitors
in unrelated cell lines. Furthermore, we show that this block
in NFUB activation is due to the prevention of inducible IUB
phosphorylation.
The CaM inhibitors employed in this study are small or-
ganic compounds that speci¢cally bind to CaM and prevent it
from interacting with its target proteins [33,36]. W7 and W13
have similar a⁄nities for CaM. W5 and W12 are analogues of
W7 and W13, respectively, with lower a⁄nities for CaM [33^
35]. In agreement with this, we see that the inhibition pro¢le
both for the W7/W13 pair and for the W5/W12 pair is similar,
and that the lower CaM-a⁄nity drugs are correspondingly
less inhibiting (Fig. 2A and B). Calmidazolium is completely
unrelated in structure and has a much higher a⁄nity for CaM
[36,37], again in accordance with the NFUB inhibition pro¢le
we obtained (Fig. 2B). The correlation between the reported
relative CaM inhibiting activity of these drugs and our results
argues that the e¡ect on NFUB activation is due to speci¢c
inhibition of CaM. This is further supported by the observed
decreased potency of a CaM inhibitor when CaM is overex-
pressed (Fig. 2C).
It is notable that we ¢nd that NFUB activation is dependent
on CaM even in the absence of Ca2 induction by ionophore.
W7 is reported to bind speci¢cally to Ca2-loaded CaM [44].
This indicates that W7 blockage of NFUB activation is due to
inhibition of the basal level of Ca2-loaded CaM. Alterna-
tively, CaM may function independently of Ca2, in line
with several previously reported Ca2-independent CaM regu-
lated processes [45^48]. This alternative would infer that while
mediating IUB phosphorylation, CaM exists in an alternative
conformation that is susceptible to W7 binding, perhaps
through association with another protein(s).
The identi¢cation of CaM involvement in the phosphoryla-
tion of IUB is a step forward in understanding the mechanism
by which IUB becomes phosphorylated. Much progress has
recently been made in this area with the identi¢cation of
500^900-kDa multisubunit IUB kinase (IKK) complexes
[9,11,49]. Two kinase components of IKK, IKKK and
IKKL, were subsequently cloned and shown to mediate cyto-
kine-induced phosphorylation of IUB [8^12]. The assembly
of these kinases into an active kinase complex is mediated
by the regulatory proteins NEMO/IKK(g) and IKAP
(reviewed in [50]). The remaining components of IKK and
the exact mechanism of its regulation are still to be resolved.
In addition to IKK, IUB phosphorylation has been shown
to be mediated by the 90-kDa ribosomal S6 kinase (p90rsk)
[6,7] and the double-stranded RNA-dependent protein kinase
PKR [4,5] in response to phorbol ester and dsRNA, respec-
tively. It is clear that the regulation of IUB phosphorylation
is a complex process, and since such a range of unrelated
stimuli can activate NFUB it is plausible that di¡erent kinases
mediate di¡erent signals. We have preliminary evidence that
CaM is involved in NFUB activation by a range of stimuli
(data not shown), which would imply that diverse signalling
pathways have a common step at which CaM has a funda-
mental role. Thus, CaM may function at a late stage of the
path to IUB phosphorylation, perhaps by enabling a produc-
tive interaction between the NFUB-IUB complex and the rel-
evant IUB kinase(s) or serving another kinase regulatory func-
tion.
In summary, we have identi¢ed CaM as a key component
of NFUB activation. Further analysis of the role of CaM in
this critical phosphorylation of IUB will be important for
understanding the mechanism and regulation of NFUB acti-
vation and may have implications for future therapeutic mod-
ulation of NFUB activity.
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